Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - gemcitabine as hydrochloride - powder for solution for infusion - gemcitabine as hydrochloride 1000 mg - gemcitabine - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer.gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 1000 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 200 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - dacarbazine as citrate - powder for solution for inj/inf - dacarbazine as citrate 500 mg/vial - dacarbazine - decarbazine is indicated for the treatment of patients with metastatic malignant melanoma. further indications for dacarbazine as part of a combination chemotherapy in advanced hodgkin's disease as a second line.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 100 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Iżrael - Ingliż - Ministry of Health

tzamal bio-pharma ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 55834 - press-fit hip femur prosthesis, one-piece - quadra-p collared is a straight triple tapered femoral stem of rectangular cross-section with a medial collar protrusion, developed by medacta international together with a group of surgeons for use in total or partial hip arthroplasty for primary or revision surgery. quadra-p collared is a cementless collared stem in titanium-niobium alloy with titanium plasma spray coating (mectagrip) on the proximal area and ha coating on the shaft. device intended for use in total or partial hip arthroplasty to provide increased patient mobility and reduced pain by replacing the damaged hip joint, in primary or revision surgery. total hip arthroplasty is indicated in the following cases: ? severely painful and/or disabled joint as a result of arthrosis, traumatic arthritis, rheumatoid polyarthritis or congenital hip dysplasia. ? avascular necrosis of the femoral head. ? acute traumatic fracture of the femoral head or neck. ? failure of previous hip surgery: joint reconstruction, internal fixation, arthrodesis, partial hip arthroplasty, hip resurfacing replacement or total hip arthroplasty. partial hip arthroplasty is indicated in the following cases: ? acute traumatic fracture of the femoral head or neck. ? non-union of femoral neck fracture. ? avascular necrosis of the femoral head. ? primary pathology involving the femoral head but with a non deformed acetabulum.

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

medacta australia pty ltd - 62782 - optical surgical navigation device tracking system - the shoulder nextar? platform supports the surgeon during glenoid implantation in shoulder replacement procedures providing information on bone preparation, instrument guidance, and implant positioning. the shoulder nextar? platform works in conjunction with nextar? stereotaxic instruments and general surgical instruments to implant the medacta shoulder system. as an optional display, the smart glasses can be used auxiliary to the shoulder nextar? platform to view the same 2d stereotaxic information as presented by the shoulder nextar? platform. the shoulder nextar? stereotaxic instruments are to support the surgeon during specific orthopedic surgical procedures by providing information on bone preparation, instrument guidance, and implant positioning. once registered, the nextar? stereotaxic instruments provide reference to a patient's rigid anatomical structures on the surface of the glenoid that are identified relative to preoperative c.t. based planning. the smart glasses should not be relied upon solely and should always be used in conjunction with the primary computer display.